92
Participants
Start Date
December 4, 2023
Primary Completion Date
January 15, 2027
Study Completion Date
January 15, 2028
CTM Boost
Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
PRP
"PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon."
AHN Wexford Health & Wellness Pavilion, Wexford
AHN Wexford Hospital, Wexford
Allegheny Health Network Allegheny General Hospital, Pittsburgh
Allegheny Health Network Federal North Medical Office Building, Pittsburgh
Connective Tissue Matrix Biomedical, LLC
UNKNOWN
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
OTHER